ID No. | Gender | Age | Final-dose (mg) | CBZ-concentration in blood (ug/ml) | CBZ-concentration / Final dose (Ratio) | Seizure-frequency | Course of disease (year) | EHPX1 methylation |
---|---|---|---|---|---|---|---|---|
1 | M | 45 | 600 | 8.3 | 14.1/1000 | 1–2/year | 4 | 32% |
2 | F | 38 | 400 | 4.1 | 10.2/1000 | 2–3/year | 5 | 6% |
3 | F | 46 | 700 | 6.4 | 8.9/1000 | 1/year | 3 | 28% |
4 | M | 41 | 600 | 7.2 | 12.2/1000 | – | 4 | 25% |
5 | M | 35 | 800 | 6.8 | 8.5/1000 | – | 4 | 27% |
6 | M | 37 | 200 | 2.6 | 13.0/1000 | 2–3/year | 5 | 24% |
7 | F | 40 | 600 | 5.7 | 9.7/1000 | 1–2/year | 6 | 23% |
8 | F | 43 | 600 | 5.3 | 9.0/1000 | – | 4 | 16% |
9 | M | 48 | 800 | 7.2 | 9.0/1000 | 1–2/year | 5 | 12% |
10 | M | 39 | 600 | 5.6 | 9.5/1000 | – | 2 | 27% |
11 | F | 43 | 600 | 5.2 | 10.9/1000 | – | 2 | 32% |
12 | F | 50 | 700 | 6.4 | 8.9/1000 | 1–2/year | 3 | 24% |
13 | F | 47 | 600 | 5.7 | 9.7/1000 | 1–2/year | 1 | 11% |
14 | M | 52 | 600 | 6.4 | 10.9/1000 | – | 3 | 13% |
15 | F | 33 | 800 | 7.5 | 9.4/1000 | 3–4/year | 4 | 17% |
16 | M | 54 | 700 | 7.1 | 9.9/1000 | 2–3/year | 2 | 20% |
17 | M | 36 | 600 | 6.7 | 11.4/1000 | – | 3 | 24% |
18 | M | 38 | 600 | 6.8 | 11.6/1000 | – | 2 | 28% |
19 | F | 40 | 600 | 5.5 | 9.4/1000 | 1–2/year | 6 | 16% |
20 | M | 42 | 400 | 4.6 | 11.5/1000 | – | 4 | 30% |
21 | F | 44 | 600 | 5.5 | 9.4/1000 | 2–3/year | 3 | 26% |
22 | M | 48 | 400 | 4.7 | 11.8/1000 | – | 4 | 22% |
23 | F | 39 | 400 | 4.9 | 12.3/1000 | – | 3 | 17% |
24 | M | 36 | 700 | 6.0 | 8.4/1000 | 1–2/year | 3 | 20% |
25 | F | 47 | 600 | 5.9 | 10.0/1000 | 1–2/year | 2 | 14% |